De novo metastatic disease at the time of initial diagnosis is considered as a poor prognostic factor in prostate cancer patients. Progesterone receptor (PR) status and its prognostic value in patients with metastatic prostatic adenocarcinoma is still a matter of controversy. This study aims to define this issue and if it affects patient prognosis. It is a cohort study that was conducted in Clinical Oncology and Nuclear Medicine Department, Mansoura University Hospital. It included 50 patients diagnosed with metastatic prostatic adenocarcinoma. Histopathological examination of the biopsies was confirmed and PR status was assessed using immunohistochemistry (IHC) as a primary end point of the study. Clinicopathological, treatment and survival data were collected. PR status and clinicopathological parameters were correlated to the patient’s survival. This work revealed PR positivity in nearly half of the cohort study cases (48%). Patients with positive PR had statistically insignificant better OS with restricted mean survival time (RMST) at 24 months of 22.7 vs. 21.7 months (P= 0.2) and PFS with RMST at 24 months of 19.6 vs. 17.3 months (P= 0.16). In conclusion, although it has not been proven to have a statistically significant prognostic value, this study has confirmed PR positivity in some cases that may raise the possibility of a new hormonal pathway that could be targeted in the metastatic prostatic adenocarcinoma.